… duties and loopholes persists Pharmaceuticals were excluded from President … $70 million for the drug’s greater China commercialization … will become Marubeni’s “pharmaceutical strategic platform.” After 2029, … $60M deal 8. Eisai offloads proton pump inhibitor …

… submissions globally with both Eisai and Biogen co-commercializing … US Food and Drug Administration (FDA) accepted Eisai’s Biologics … backbone anti-amyloid therapy. Eisai and Biogen have been … commercialization of AD treatments. Eisai obtained the global rights …

… such as enhanced pharmacokinetic and pharmacodynamic properties and antibody engineering … the Antibody Drug Conjugates Market ADC Therapeutics Astellas Pharma AstraZeneca Byondis … Cerbios-Pharma Senior Vice President and Chief Scientific Officer, Eisai Chief …

… Eisai to Divest Rights for Pariet in China to Peak Pharma … TOKYO, Apr 1, 2025 - (JCN Newswire) - Eisai … Peak Pharma has commenced marketing activities, while Eisai will … the healthcare space, including pharmaceutical, biotech, medical technology, …

Indiana-based pharmaceutical company Eli Lilly is part … disease worldwide. One of its drugs was recently approved in the … against the approval of the drug on Thursday. Kisunla, also known … Inc. in Cambridge, Mass. and Eisai Co in Japan. It was …

… she tried a new drug from Eisai Co. that promised to … That follows Australia’s drug regulators deciding against making Leqembi … Europe, regulators first rejected Eisai’s drug for similar reasons in … with the drug, according to clinical trials. In Eisai’s main …

… abnormalities (ARIA) with the drug, like brain bleeding and … EU compared to rivals Eisai and Biogen, whose amyloid … pointing out that the drug has already been approved … subcutaneous formulation of blockbuster cancer drug Opdivo (nivolumab). Meanwhile, the …

… That follows Australia’s drug regulators deciding against making … , regulators first rejected Eisai’s drug for similar reasons in … with the drug, according to clinical trials. In Eisai’s … seizures. In a statement, Eisai acknowledged “rare post-marketing …

… the benefits of the new drug, Kisunla, did not … hopes discussions about the drug continue with the agency … re-examination. The Indianapolis drugmaker noted that Kisunla has already … a similar drug, Leqembi, from Japanese drugmaker Eisai. The drugs are the …

… primarily aiming to produce pharmaceutical products such as drugs, vaccines, and biologics … well-known that manufacturing drugs and other pharmaceutical compounds generate a lot … of various Japanese pharma companies such as Astellas, Eisai, Daiichi Sankyo, …